Crossref
Long-Term Cardiovascular Safety of Melatonin: Why Dose, Duration, and Patient Phenotype Matter
Cureus · 03.11.2026
DOI: 10.7759/cureus.119054 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cureus, erschienen am 03.11.2026. Verfasst von Esteban Zavaleta-Monestel und 3 weiteren Autor:innen. Die Arbeit nennt 17 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Zavaleta-Monestel, E., Gamboa, J. A. C., Mora, K. C., & Mora-Jiménez, J. (2026). Long-Term Cardiovascular Safety of Melatonin: Why Dose, Duration, and Patient Phenotype Matter. Cureus. https://doi.org/10.7759/cureus.119054
Vancouver
Zavaleta-Monestel E, Gamboa JAC, Mora KC, Mora-Jiménez J. Long-Term Cardiovascular Safety of Melatonin: Why Dose, Duration, and Patient Phenotype Matter. Cureus. 2026. doi:10.7759/cureus.119054
BibTeX
@article{ZavaletaMonestel2026,
author = {Zavaleta-Monestel, Esteban and Gamboa, José A Castro and Mora, Kevin Cruz and Mora-Jiménez, Jeaustin},
title = {Long-Term Cardiovascular Safety of Melatonin: Why Dose, Duration, and Patient Phenotype Matter},
journal = {Cureus},
year = {2026},
doi = {10.7759/cureus.119054}
}
EUVIMED